









Markets
/
Stocks
/
nasdaq-indv
/

Indivior PLC

INDV

34.360USD

-0.090-0.26%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

4.29BMarket Cap

34.93P/E TTM



Indivior PLC

34.360

-0.090-0.26%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Indivior PLC

Currency: USD Updated: 2026-02-06

Key Insights

Indivior PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 159 in the Pharmaceuticals industry.Institutional ownership is very low.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 45.57.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Indivior PLC's Score

Industry at a Glance

Industry Ranking

63 / 159

Overall Ranking

177 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Indivior PLC Highlights

StrengthsRisks

Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 31.85% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 34.93, at a high 3-year percentile range.

Held by HOTCHKIS & WILEY

Star Investor HOTCHKIS & WILEY holds 1.48K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

45.571

Target Price

+31.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Indivior PLC is 8.00, ranking 90 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 314.00M, representing a year-over-year increase of 2.28%, while its net profit experienced a year-over-year increase of 950.00%.

Score

Industry at a Glance

Previous score

8.00

Change



Financials

6.95

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.12

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.43

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.50

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Indivior PLC's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Indivior PLC is 6.87, ranking 109 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 34.93, which is 2261.98% below the recent high of 825.08 and 344.12% above the recent low of -85.28.

Score

Industry at a Glance

Previous score

6.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 63/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Indivior PLC is 8.57, ranking 25 out of 159 in the Pharmaceuticals industry. The average price target is 36.00, with a high of 41.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

45.571

Target Price

+31.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Indivior PLC

INDV

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Indivior PLC is 7.32, ranking 66 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 36.49 and the support level at 31.97, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.24

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.099

Neutral

RSI(14)

49.101

Neutral

STOCH(KDJ)(9,3,3)

43.722

Sell

ATR(14)

1.285

Low Volatility

CCI(14)

15.755

Neutral

Williams %R

38.568

Buy

TRIX(12,20)

-0.041

Sell

StochRSI(14)

1.400

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

34.720

Sell

MA10

34.694

Sell

MA20

34.122

Buy

MA50

34.867

Sell

MA100

30.716

Buy

MA200

23.698

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.79M

+54.61%

Oaktree Capital Management, L.P.

Star Investors

7.11M

-18.71%

Madison Avenue Partners LP

6.46M

-18.41%

Goldman Sachs & Company, Inc.

6.41M

+1302.98%

Two Seas Capital LP

6.21M

-32.87%

Morgan Stanley & Co. LLC

5.58M

+934.24%

Deerfield Management Company, L.P.

4.61M

-33.95%

Newtyn Management, LLC

4.20M

+61.10%

The Vanguard Group, Inc.

Star Investors

3.44M

-38.82%

Sirovich (Matthew I.)

3.42M

+7.87%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Indivior PLC is 6.43, ranking 54 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.